Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells
Felix C. E. Vogel(German Cancer Research Center), Alexander Roesch(University of Regensburg), Susanne Horn(Vrije Universiteit Brussel), Christoph Magnes(Joanneum Research), Batool Shannan(Vrije Universiteit Brussel), Dirk Schadendorf(University of Mannheim), Marija Trajkovic‐Arsic(German Cancer Research Center), Jens T. Siveke(German Cancer Research Center), Natalie Bordag(Joanneum Research), Elmar Zügner(Joanneum Research), Heike Chauvistré(Vrije Universiteit Brussel), Renáta Váraljai(Vrije Universiteit Brussel)
Cited by 36
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
|Cell|2018|1.4k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
Cardioprotection and lifespan extension by the natural polyamine spermidine
|Nature Medicine|2016|1.1k